Metraipolis › archive › dc_98179a7ef129
Impact of Glucagon-Like Peptide-1 Agonists on Hepatocellular Carcinoma Risk and Management in Type 2 Diabetes Mellitus: A Scoping Review — Europe PMC PMID:41607999
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41607999
- DOI
- 10.7759/cureus.100252
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T09:02:40.807Z
- SHA-256 of the archived text
6e02cd4271283f219ee10bfc6d64ace0395477f679e9d422d299827eb5e3d701- Stable URL of this page
https://metraipolis.com/documento/dc_98179a7ef129
How to cite
Impact of Glucagon-Like Peptide-1 Agonists on Hepatocellular Carcinoma Risk and Management in Type 2 Diabetes Mellitus: A Scoping Review — Europe PMC PMID:41607999 — Europe PMC (en), https://europepmc.org/article/MED/41607999 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_98179a7ef129 (Metraipolis archive dc_98179a7ef129, sha256 6e02cd4271283f219ee10bfc6d64ace0395477f679e9d422d299827eb5e3d701)
BibTeX
@misc{dc98179a7ef129,
title = {Impact of Glucagon-Like Peptide-1 Agonists on Hepatocellular Carcinoma Risk and Management in Type 2 Diabetes Mellitus: A Scoping Review — Europe PMC PMID:41607999},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41607999},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_98179a7ef129; sha256 6e02cd4271283f219ee10bfc6d64ace0395477f679e9d422d299827eb5e3d701},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41607999. Agents can read the archived copy with the MCP tool read_document.